ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
60 610,35
0,49%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Organon and Co (OGN)

  7. Organon and Co (OGN) Actualités

OGN

Organon (OGN)

Organon and Co
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:OGN
DateHeureSourceTitreSymboleSociété
11/06/202421h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
06/06/202413h00Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
24/05/202419h59Business WireEuropäische Arzneimittel-Agentur (EMA) validiert Einreichungen von Henlius und Organon für den Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten HLX14NYSE:OGNOrganon and Co
24/05/202419h59Business WireL’Agence européenne des médicaments (EMA) entérine les dépôts de Henlius et d’Organon pour le candidat biosimilaire HLX14 de Prolia ® et Xgeva ® (denosumab)NYSE:OGNOrganon and Co
24/05/202417h29Business Wire欧州医薬品庁（EMA）、ヘンリウスとオルガノンによるProlia ® およびXgeva ® （デノスマブ）バイオシミラー候補HLX14を認証NYSE:OGNOrganon and Co
24/05/202412h00Business WireEuropean Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14NYSE:OGNOrganon and Co
08/05/202402h20Business WireOrganon Announces Pricing of $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
07/05/202413h58Business WireOrganon Announces Proposed $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
02/05/202413h30Business WireOrganon Reports Results for the First Quarter Ended March 31, 2024NYSE:OGNOrganon and Co
09/04/202414h13Business WireProlia ® とXgeva ® （デノスマブ）との第3相比較臨床試験でバイオシミラー候補HLX1​​4が主要評価項目を達成NYSE:OGNOrganon and Co
08/04/202420h31Business WireKlinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre EndpunkteNYSE:OGNOrganon and Co
08/04/202420h31Business WireL'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primairesNYSE:OGNOrganon and Co
08/04/202412h15Business WireOrganon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024NYSE:OGNOrganon and Co
08/04/202412h00Business WirePhase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary EndpointsNYSE:OGNOrganon and Co
08/03/202415h01PR Newswire (Canada)On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's healthNYSE:OGNOrganon and Co
08/03/202415h01PR Newswire (Canada)À l'occasion de la Journée internationale des femmes, Organon Canada encourage les entreprises à Investir en elle et à lutter contre les inégalités entre les genres par la santé des femmesNYSE:OGNOrganon and Co
26/02/202414h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:OGNOrganon and Co
20/02/202414h00Business WireOrganon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National FormularyNYSE:OGNOrganon and Co
15/02/202413h30Business WireOrganon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023NYSE:OGNOrganon and Co
01/02/202413h30Business WireOrganon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024NYSE:OGNOrganon and Co
10/01/202413h33Business WireOrganon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and OlderNYSE:OGNOrganon and Co
08/01/202413h30Business WireOrganon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlookNYSE:OGNOrganon and Co
21/12/202313h30Business WireOrganon To Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:OGNOrganon and Co
19/12/202314h30Business WireOrganon et Lilly concluent un accord de commercialisation en Europe pour deux médicaments contre la migraineNYSE:OGNOrganon and Co
19/12/202310h11Business WireOrganon と Lilly、ヨーロッパで 2 種類の片頭痛薬商業化契約を締結NYSE:OGNOrganon and Co
19/12/202303h26Business WireOrganon und Lilly schließen Vermarktungsvereinbarung für zwei Migräne-Medikamente in EuropaNYSE:OGNOrganon and Co
18/12/202313h30Business WireOrganon & Lilly Enter Commercialization Agreement in Europe for Two Migraine MedicinesNYSE:OGNOrganon and Co
21/11/202313h30Business WireOrganon To Present at the Piper Sandler 35th Annual Healthcare ConferenceNYSE:OGNOrganon and Co
07/11/202322h15GlobeNewswire Inc.Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®NYSE:OGNOrganon and Co
03/11/202312h52Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:OGNOrganon and Co
 Showing the most relevant articles for your search:NYSE:OGN

Dernières Valeurs Consultées

BIT
P1TMI9
BNP Paribas Issuance
BIT
F38679
Vontobel Financial Produ...
COIN
XSTCUSD
NASDAQ
ABBKPXX
Morgan Stanley Bank Na P...
TG
NBC
National Bank Of Canada
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés